M&A / Deals

NewLimit’s $435M megaround; Lilly’s busy dealmaking week

BioPharma Dive

The anti-aging biotech has secured one of the year s biggest venture fundings to bring its first drug into testing.

Read full story

pharminent June 3, 2026 (Last updated: June 4, 2026)

BioPharma Dive

The anti-aging biotech has secured one of the year s biggest venture fundings to bring its first drug into testing.

Read full story